Repare Therapeutics Announces Positive Initial Data from Pha

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes


Overall response of 33.3% across all tumor types and...

Related Keywords

Texas , United States , Ukraine , Canada , Boston , Massachusetts , Houston , Timothya Yap , Maria Koehler , Lloydm Segal , Twitter , Repare Therapeutics Inc , Head Of Clinical Development , Exchange Commission , International Conference On Molecular , Company Quarterly Report On Form , Linkedin , University Of Texas Md Anderson Cancer Center , Company Nasdaq , Company Virtual Webcast Event , Department Of Investigational Cancer Therapies Phase , Therapeutics Discovery Division , Company Annual Report On Form , Repare Therapeutics , Molecular Targets , Cancer Therapeutics , Chief Executive Officer , Investigational Cancer Therapies , Vice President , Clinical Development , Cancer Center , Principal Investigator , Initial Findings , Chief Medical Officer , Virtual Webcast Event , Private Securities Litigation Reform Act , Annual Report , Des March , Quarterly Report , Markets ,